Table 2.
Treatment Exposures Associated With Latent Class Membership: No CRT
| Variable | Externalizing Versus Well Adjusted | Internalizing Versus Well Adjusted | Global Symptoms Versus Well Adjusted | |||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | |
| Age, years | ||||||
| At diagnosis | 1.0 | 1.0 to 1.1 | 1.0 | 0.9 to 1.0 | 1.1 | 1.0 to 1.2 |
| At survey | ||||||
| 12-14 | 1.2 | 1.0 to 1.5 | 1.4 | 1.1 to 1.8 | 1.8 | 1.3 to 2.5 |
| 15-17 | 1.0 | 1.0 | 1.0 | |||
| Sex | ||||||
| Female | 1.0 | 1.0 | 1.0 | |||
| Male | 1.0 | 0.8 to 1.2 | 0.8 | 0.6 to 1.0 | 1.2 | 0.9 to 1.7 |
| Race | ||||||
| White | 1.0 | 1.0 | 1.0 | |||
| Black | 1.3 | 0.9 to 2.0 | 0.5 | 0.3 to 1.1 | 2.0 | 1.1 to 3.5 |
| Other | 1.4 | 1.0 to 2.0 | 1.1 | 0.7 to 1.7 | 1.1 | 0.6 to 2.0 |
| IT methotrexate, mg/m2 | ||||||
| None | 1.0 | 1.0 | 1.0 | |||
| < 230 | 0.5 | 0.3 to 0.8 | 2.0 | 1.0 to 3.9 | 1.6 | 0.7 to 3.9 |
| ≥ 230 | 0.5 | 0.3 to 0.8 | 1.1 | 0.6 to 2.0 | 0.7 | 0.3 to 1.7 |
| High-dose IV methotrexate, g | ||||||
| < 4.3 | 1.0 | 1.0 | 1.0 | |||
| ≥ 4.3 | 1.1 | 0.8 to 1.5 | 0.5 | 0.3 to 0.8 | 1.5 | 0.9 to 2.4 |
| Cytarabine | ||||||
| None | 1.0 | 1.0 | 1.0 | |||
| Yes | 1.1 | 0.8 to 1.7 | 1.6 | 0.9 to 2.7 | 1.0 | 0.5 to 1.8 |
| Corticosteroids | ||||||
| None | 1.0 | 1.0 | 1.0 | |||
| Nondexamethasone | 1.9 | 1.2 to 2.8 | 0.5 | 0.3 to 0.9 | 1.0 | 0.5 to 2.1 |
| Dexamethasone | 1.1 | 0.7 to 1.7 | 0.8 | 0.5 to 1.5 | 0.6 | 0.3 to 1.4 |
| Anthracyclines, mg/m2 | ||||||
| None | 1.0 | 1.0 | 1.0 | |||
| < 300 | 1.1 | 0.8 to 1.4 | 0.8 | 0.6 to 1.1 | 0.8 | 0.6 to 1.3 |
| ≥ 300 | 1.0 | 0.7 to 1.5 | 0.8 | 0.5 to 1.3 | 0.7 | 0.4 to 1.3 |
NOTE. In all, 2,584 participants were included in this analysis. Bold font indicates estimates with a false discovery rate ≤ 10%.
Abbreviations: CRT, cranial radiation therapy; IT, intrathecal; IV, intravenous; OR, odds ratio.